A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab
Main Article Content
Keywords
High risk Multiple Myeloma, hyperammonemia
Abstract
n.
Downloads
Download data is not yet available.
Abstract 535
PDF Downloads 765
HTML Downloads 328
References
1) Costa, L. J., & Usmani, S. Z. (2020). Defining and Managing High-Risk Multiple Myeloma: Current Concepts, Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 18(12), 1730-1737. Retrieved May 20, 2022, from https://jnccn.org/view/journals/jnccn/18/12/article-p1730.xml
2) Ikewaki J, Ogata M, Imamura T, Kohno K, Nakayama T, Kadota J. Development of hyperammonemic encephalopathy in patients with multiple myeloma may be associated with the appearance of peripheral blood myeloma cells. Leuk Lymphoma. 2009 Apr;50(4):667-9. doi: 10.1080/10428190902741489. PMID: 19373670.
3) Jaime Lora-Tamayo, Xavier Palom, José Sarrá, Oriol Gasch, Virginia Isern, Alberto Fernández de Sevilla, Ramón Pujol, Multiple Myeloma and Hyperammonemic Encephalopathy: Review of 27 Cases, Clinical Lymphoma and Myeloma, Volume 8, Issue 6, 2008, Pages 363-369, ISSN 1557-9190, https://doi.org/10.3816/CLM.2008.n.054.
4) Gertz MA, Buadi FK. Plasma cell leukemia. Haematologica. 2010;95(5):705-707. doi:10.3324/haematol.2009.021618
5) Howman R , Th akerer A , Pitman M , et al . Bortezomib, cyclophosphamide, and dexamethasone: highly eff ective for rapid reversal of myeloma-associated hyperammonemic encephalopathy . Leuk Lymphoma 2010 ; 51 : 2299 – 2302.
6) Amit Patel, Umeer Waheed, Stephen J. Brett, Amin Rahemtulla, Jane F. Apperley & Parind B. Patel (2014) Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate and dexamethasone therapy, Leukemia & Lymphoma, 55:1, 198-200
7) Anthony Pham, John L. Reagan, Jorge J Castillo; Plasma Cell Myeloma Causing Hyperammonemia Associated with High Inpatient Mortality. Blood 2012; 120 (21): 5002. doi: https://doi.org/10.1182/blood.V120.21.5002.5002
8) Murtaza G, Lu H, Faqah A, Konowitz N, Kuruvilla A, Adhikari S. Multiple Myeloma-Induced Hyperammonemic Encephalopathy. J Hematol. 2017;6(1):29-31. doi:10.14740/jh322e
2) Ikewaki J, Ogata M, Imamura T, Kohno K, Nakayama T, Kadota J. Development of hyperammonemic encephalopathy in patients with multiple myeloma may be associated with the appearance of peripheral blood myeloma cells. Leuk Lymphoma. 2009 Apr;50(4):667-9. doi: 10.1080/10428190902741489. PMID: 19373670.
3) Jaime Lora-Tamayo, Xavier Palom, José Sarrá, Oriol Gasch, Virginia Isern, Alberto Fernández de Sevilla, Ramón Pujol, Multiple Myeloma and Hyperammonemic Encephalopathy: Review of 27 Cases, Clinical Lymphoma and Myeloma, Volume 8, Issue 6, 2008, Pages 363-369, ISSN 1557-9190, https://doi.org/10.3816/CLM.2008.n.054.
4) Gertz MA, Buadi FK. Plasma cell leukemia. Haematologica. 2010;95(5):705-707. doi:10.3324/haematol.2009.021618
5) Howman R , Th akerer A , Pitman M , et al . Bortezomib, cyclophosphamide, and dexamethasone: highly eff ective for rapid reversal of myeloma-associated hyperammonemic encephalopathy . Leuk Lymphoma 2010 ; 51 : 2299 – 2302.
6) Amit Patel, Umeer Waheed, Stephen J. Brett, Amin Rahemtulla, Jane F. Apperley & Parind B. Patel (2014) Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate and dexamethasone therapy, Leukemia & Lymphoma, 55:1, 198-200
7) Anthony Pham, John L. Reagan, Jorge J Castillo; Plasma Cell Myeloma Causing Hyperammonemia Associated with High Inpatient Mortality. Blood 2012; 120 (21): 5002. doi: https://doi.org/10.1182/blood.V120.21.5002.5002
8) Murtaza G, Lu H, Faqah A, Konowitz N, Kuruvilla A, Adhikari S. Multiple Myeloma-Induced Hyperammonemic Encephalopathy. J Hematol. 2017;6(1):29-31. doi:10.14740/jh322e